Advancing the Science of Phosphate Absorption: Paracellular Pathway and Implications for Phosphorus Management
Ardelyx invites you to join our session Advancing the Science of Phosphate Absorption, Paracellular Pathway and Implications for Phosphorus Management. Dr. Kamyar Kalantar-Zadeh will be presenting New Understanding of Phosphate Absorption May Explain Challenges in Phosphorus Management. Dr. Kalantar-Zadeh will discuss the advancing science of gastrointestinal phosphate absorption with new insights into our understanding of the primacy of the paracellular pathway and how this understanding sheds light on the current challenges clinicians face in the management of hyperphosphatemia. Dr. Glenn Chertow, will present Tenapanor: An Investigational Therapy for the Treatment of Hyperphosphatemia.* This presentation will introduce tenapanor, a novel, non-binder therapy in development for the treatment of hyperphosphatemia that specifically targets and blocks phosphorus absorption through the paracellular pathway. In addition to presenting the mechanism of action of this new therapy in development, Dr. Chertow will present data from the tenapanor phase 3 clinical trial program in adult patients with Chronic Kidney Disease on dialysis.
* Tenapanor is an investigational drug in development for the control of serum phosphorus in patients with CKD on dialysis. Efficacy and safety for the control of serum phosphorus in patients with CKD on dialysis have not been established by the FDA.